Author

Manuel Rhiel

University of FreiburgORCID 0000-0003-0741-2780Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Manuel Rhiel1 paper

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Approach:genetic perturbation / CRISPR· 2 Assay:ATAC-seq· 1 Assay:CITE-seq· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

Tatjana I. CornuiD· 3 shared Toni CathomeniD· 3 shared Geoffroy AndrieuxiD· 2 shared Alessandro SinopoliiD· 1 shared Alvin HsuiD· 1 shared Amélie WiederkehriD· 1 shared André LieberiD· 1 shared Andreas B. DiendorferiD· 1 shared

Activity by Year

2026-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

Tatjana I. CornuORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BioengineeringbioRxivPreprintJul 8, 2026

CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates β-thalassemia model

Romina Marone, Rosalba Lepore, Kiriaki Paschoudi…·Lukas T. Jeker

This paper demonstrates a method using CD117-blocking antibody and epitope-engineered HSPCs to treat β-thalassemia without myeloablative conditioning.

DOI 10.64898/2026.07.07.736903

𝕏 PostBluesky

Cancer BiologybioRxivPreprintFeb 27, 2026

Next-generation all-in-one CRISPR/Cas9 multiply-edited CD30CAR-T cells:Potency despite risk of translocations

Jan-Malte Kleid, Michael Damrat, Milita Darguzyte…·Renata Stripecke

This study develops next-generation CD30CAR-T cells using CRISPR/Cas9 for multiplex editing, showing high potency but risks of translocations with combined knockouts.

DOI 10.64898/2026.02.27.708432

𝕏 PostBluesky

Molecular BiologybioRxivPreprintFeb 19, 2026

Castling, a novel therapeutic concept for rewiring pathological gene-expression networks, enabled by the TRIPLE technology

Dinu Antony, Maria Silvia Roman Azcona, Hagar Kalinski…·Claudio Mussolino

The paper introduces a therapeutic strategy called castling to correct gene-expression imbalances by rewiring miRNA regulation using the TRIPLE genome-editing technology.

DOI 10.64898/2026.01.28.702195

humanCRISPR screen

𝕏 PostBluesky